| Literature DB >> 25548779 |
Fadhil Lafta Faraj1, Maryam Zahedifard2, Mohammadjavad Paydar3, Chung Yeng Looi3, Nazia Abdul Majid2, Hapipah Mohd Ali4, Noraini Ahmad4, Nura Suleiman Gwaram4, Mahmood Ameen Abdulla5.
Abstract
Two new synthesized and characterized quinazoline Schiff bases 1 and 2 were investigated for antiEntities:
Mesh:
Substances:
Year: 2014 PMID: 25548779 PMCID: PMC4274848 DOI: 10.1155/2014/212096
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Quinazoline-4-one.
Figure 2The reaction pathway for the synthesis of compounds (1) and (2).
The IC50 concentration of the quinazolinone-based compounds against MCF-7, MCF-10, and WRL-68 cell lines after 24, 48, and 72 h.
| Compound | Cell line | Classification | IC50 ( | ||
|---|---|---|---|---|---|
| 24 h | 48 h | 72 h | |||
| (1) | MCF-7 | Breast cancer cells | 8.063 × 10−6 mol/L | 7.599 × 10−6 mol/L | 6.246 × 10−6 mol/L |
| MCF-10 | Normal breast cells | 0.483 × 10−6 mol/L | 0.483 × 10−6 mol/L | 0.483 × 10−6 mol/L | |
| WRL-68 | Normal hepatic cells | 0.773 × 10−6 mol/L | 0.773 × 10−6 mol/L | 0.773 × 10−6 mol/L | |
|
| |||||
| (2) | MCF-7 | Breast cancer cells | 7.609 × 10−6 mol/L | 6.621 × 10−6 mol/L | 5.910 × 10−6 mol/L |
| MCF-10 | Normal breast cells | 0.483 × 10−6 mol/L | 0.483 × 10−6 mol/L | 0.483 × 10−6 mol/L | |
| WRL-68 | Normal hepatic cells | 0.773 × 10−6 mol/L | 0.773 × 10−6 mol/L | 0.773 × 10−6 mol/L | |
|
| |||||
| Doxorubicin | MCF-7 | Breast cancer cells | 4.471 × 10−6 mol/L | 4.195 × 10−6 mol/L | 3.827 × 10−6 mol/L |
Figure 51H NMR spectrum of compound (1) in (400 MHz, DMSO-d6).
Figure 613C NMR spectrum of compound (1) in (100 MHz, DMSO-d6).
Figure 71H NMR spectrum of a compound (2) in (400 MHz, DMSO-d6).
Figure 813C NMR spectrum of compound (2) in (100 MHz, DMSO-d6).
Figure 9Crystal structure of compound (1).
X-ray crystallographic data table for compound 1.
| Identification code | Compound 1 |
|---|---|
| Empirical formula | C23H21Br2N3O4S |
| Formula weight | 595.31 |
| Temperature/K | 100(2) |
| Crystal system | Monoclinic |
| Space group | C2/c |
| a/Å | 21.906(5) |
| b/Å | 9.071(2) |
| c/Å | 25.497(6) |
| α/° | 90.00 |
| β/° | 109.622(5) |
| γ/° | 90.00 |
| Volume/Å3 | 4773(2) |
|
| 8 |
|
| 1.657 |
| m/mm−1 | 3.520 |
|
| 2384.0 |
| Crystal size/mm3 | 0.35 × 0.22 × 0.14 |
| Radiation | MoK |
| 2Θ range for data collection | 4.9 to 54° |
| Index ranges | −27 ≤ |
| Reflections collected | 12389 |
| Independent reflections | 5055 [Rint = 0.0376, Rsigma = 0.0490] |
| Data/restraints/parameters | 5055/0/318 |
| Goodness-of-fit on F2 | 1.097 |
| Final R indexes [ | R1 = 0.0500, wR2 = 0.1154 |
| Final R indexes [all data] | R1 = 0.0655, wR2 = 0.1212 |
| Largest diff. peak/hole/e Å−3 | 1.36/−0.93 |
Crystal data for compound 1 (M = 595.31): monoclinic, space group C2/c (no. 15), a = 21.906(5) Å, b = 9.071(2) Å, c = 25.497(6) Å, β = 109.622(5)°, V = 4773(2) Å3, Z = 8, T = 100(2) K, μ(MoKα) = 3.520 mm−1, D calc = 1.657 g/mm3, 12389 reflections measured (4.9 ≤ 2Θ ≤ 54), 5055 unique (Rint = 0.0376, Rsigma = 0.0490) which were used in all calculations. The final R1 was 0.0500 (>2sigma(I)) and wR2 was 0.1212 (all data).
Figure 10The LDH release assay revealed the significant cytotoxicity of the quinazolinone-based compound on MCF-7 cells at concentrations 4 × 10−6, 8 × 10−6, and 16 × 10−6 mol/L.
Figure 11Fluorescent micrographs of AO/PI-double-stained MCF-7 cells. (a) Untreated MCF-7 cells exhibit normal structures. (b1) and (c1) Early apoptosis features, namely, blebbing and chromatin condensation as well as late apoptotic cells, were detected after 24 h of treatment with (1) and (2). (b2) and (c2) Late apoptosis and secondary necrosis were obsereved after 48 h of treatment with (1) and (2), respectively (magnification: 200x). VI: viable cells; CC: chromatin condensation; BL: blebbing of the cell membrane; LA: late apoptosis; SN: secondary necrosis.
Figure 12Cell cycle analysis. (a) Effect of (1) and (2) on cell cycle arrest. After incubation with DMSO or different concentrations of (1) and (2) for 24 h, MCF-7 cells were stained with BrdU and phosphohistone H3 and subjected to the Cellomics ArrayScan HCS reader for cell cycle analysis. (b) Representative bar charts indicating that treatment of both compounds markedly decreased BrdU and phosphohistone H3 fluorescence intensities in treated MCF-7 cells. Data were expressed as the mean ± SD of fluorescence intensity readings for three independent experiments.
Figure 13Effect of MMD compound on the generation of ROS. The level of ROS significantly elevated at 8 × 10−6 and 16 × 10−6 mol/L concentrations.
Figure 14Effects of the Quinazoline Schiff bases on nuclear morphology, membrane permeability, mitochondrial membrane potential (MMP), and cytochrome c release. (a) Representative images of MCF-7 cells treated with medium alone and at 4 × 10−6, 8 × 10−6, and 16 × 10−6 mol/L concentrations of compounds and stained with Hoechst 33342 for nuclear, cytochrome c, membrane permeability, and MMP dyes. Both compound induced a noteworthy elevation in membrane permeability and cytochrome c release and a marked reduction in mitochondrial membrane potential (magnification: 200x). (b) Representative bar charts indicating dose-dependent increased cell permeability reduced MMP and increased cytochrome c release in treated MCF-7 cells.
Figure 15Relative luminescence time-dependent expression of caspases-3/7, -8, and -9 in MCF-7 cells treated with (1) and (2) at concentrations of 8 × 10−6 mol/L and 7.6 × 10−6 mol/L, respectively, after 24 hours incubation.
Figure 16NF-κB translocation. (a) Photographs of the intracellular targets of stained MCF-7 cells that were exposed to (1) and (2) at concentrations of 8 × 10−6 mol/L and 7.6 × 10−6 mol/L, respectively, for 3 hours and then stimulated for 30 minutes with 1 ng/mL TNF-α (NF-κB activation). (b) Representative bar chart showing translocation of TNF-α-induced NF-κB nuclear in MCF-7 cells for different concenataions.
Figure 17Histological sections in acute toxicity test (H&E staining, 20x). Histological sections of liver (first row) and kidney (second row). Untreated mices (control group) received 5 mL/kg vehicle (5% Tween 20) ((a) and (d)). Animals treated with 250 mg/kg are ((b) and (e)) and ((c) and (f)) for compounds 1 and 2, respectively. There are no significant differences in structures of liver and kidney between treated and control group.
Effects of 250 mg/kg of 1 and 2 on liver function test.
| Groups | Total protein | Albumin | Globulin | AP | ALT | AST | GGT |
|---|---|---|---|---|---|---|---|
| Vehicle |
|
|
|
|
|
|
|
| 1 (250 mg/kg) | 65 ± 1.3 | 12.9 ± 0.59 | 53.1 ± 1.8 | 91.4 ± 3.4 | 67.7 ± 4.6 | 245 ± 7.5 | 3.3 ± 0.07 |
| 2 (250 mg/kg) | 60 ± 1.0 | 11.8 ± 0.33 | 55.6 ± 1.2 | 87.2 ± 2.7 | 56.1 ± 4.2 | 264 ± 8.3 | 3.7 ± 0.09 |
Values are expressed as the means ± S.E.M. There are no statistically significant differences between the measurements of different groups. Significance was set at P < 0.05.
Effects of 250 mg/kg of 1 and 2 on renal function test.
| Groups | Sodium | Potassium | Chloride | CO2
| Anion gap | Urea |
|---|---|---|---|---|---|---|
| Vehicle |
|
|
|
|
|
|
| 1 (250 mg/kg) | 151.5 ± 0.58 | 9.5 ± 0.18 | 110.8 ± 0.27 | 22.8 ± 0.68 | 26.6 ± 0.9 | 8.4 ± 0.5 |
| 2 (250 mg/kg) | 153.3 ± 0.76 | 9.4 ± 0.2 | 114.3 ± 0.33 | 19.2 ± 0.21 | 22.7 ± 0.5 | 7.7 ± 0.8 |
Values are expressed as the means ± S.E.M. There are no statistically significant differences between the measurements of different groups. Significance was set at P < 0.05.